ARTICLE | Clinical News
FDA approves subcutaneous rituximab
July 14, 2017 7:28 PM UTC
The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said FDA approved Rituxan Hycela subcutaneous rituximab to treat previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL). The subcutaneous formulation of rituximab, a chimeric mAb against CD20 antigen, uses Enhanze recombinant human hyaluronidase (rHuPH20) drug delivery technology from Halozyme Therapeutics Inc. (NASDAQ:HALO).
It is approved in the EU for CLL, DLBCL and non-Hodgkin’s lymphoma (NHL)...